logo-loader
viewAIM ImmunoTech Inc.

AIM ImmunoTech reaches deal with Japan to test Ampligen as coronavirus treatment

Ampligen has previously been used with success in mice to treat Severe Acute Respiratory Syndrome (SARS), which is a sort of sister virus to the Wuhan coronavirus

Japanese flag
Japan’s National Institute of Infectious Diseases will kickstart testing its flagship drug as a potential treatment for the deadly new coronavirus (COVID-19)

AIM ImmunoTech Inc (NYSE American: AIM), the biopharma group, has revealed that Japan’s National Institute of Infectious Diseases will kick off testing its flagship drug Ampligen as a potential treatment for the deadly new coronavirus (COVID-19), which originated in Wuhan, China.

This experimental program to treat the virus, which is caused by SARS-CoV-2 and is related to the original SARS virus, will be conducted at the National Institute of Infectious Diseases (NIID) as well as the University of Tokyo. All testing and research will be conducted by Dr. Hideki Hasegawa, the director of Japan’s National Institute’s Influenza Virus research center and Dr. Takeshi Ichinohe, a PHD in the department of Pathology at the NIID, Department of Biological Science and Technology at Tokyo University of Science.

READ: AIM ImmunoTech says raised around $10M from public markets over past few months to support lead drug cancer candidate

Ampligen has previously been used with success in mice to treat Severe Acute Respiratory Syndrome (SARS), which is a sort of sister virus to the Wuhan coronavirus and also originated in China, but in the Guangdong province.

After a 2002 SARS outbreak in Guangdong reported more than 8,000 illnesses and more than 800 deaths, the US National Institutes of Health contracted studies with Ampligen to evaluate its effectiveness as a treatment for SARS. In those studies, Ampligen saw a 100% survival rate – “at clinically achievable human dosage levels” in experiments with mice.

“Ampligen had excellent antiviral activity against the earlier SARS coronavirus in US National Institutes of Health-contracted animal experiments,” noted Thomas Equels, AIM CEO in a statement. “In those studies of SARS-infected mice, Ampligen stands out as the only drug tested that conferred a significant survival effect: 100% of the Ampligen- treated mice survived, while none of the untreated mice survived.”

Ampligen is a Toll-Like Receptor 3 agonist based on synthetic double-stranded RNA which is also being used in clinical trials to evaluate its effectiveness in taking aim at renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple-negative metastatic breast cancer.

Quick facts: AIM ImmunoTech Inc.

Price: 2.62 USD

NYSE:AIM
Market: NYSE
Market Cap: $66.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to...

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China. Equels telling Proactive how this drug will try to be a...

4 weeks ago

2 min read